OBJECTIVE: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy. DESIGN: Retrospective study. SETTING: Specialist hospital, USA. SUBJECTS: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992. MAIN OUTCOME MEASURES: Survival and prognostic factors on multivariate analysis. RESULTS: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004). CONCLUSION: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.
No takes yet. Share an insight, caveat, or question.
G. E. Messaris (2000) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: